|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-3-29
|
|
pubmed:abstractText |
Farglitazar (GI262570), an insulin-sensitizing agent, selectively binds and activates peroxisome proliferator-activated receptor gamma (PPARgamma) and inhibits stellate cell activation. We evaluated its antifibrotic effect in patients with chronic hepatitis C that did not respond to standard-of-care therapy.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1528-0012
|
|
pubmed:author |
pubmed-author:BrigandiRichardR,
pubmed-author:ChuangWan-LongWL,
pubmed-author:Farglitizar Study Investigators,
pubmed-author:GardnerStephenS,
pubmed-author:GoodmanZacharyZ,
pubmed-author:HusaPetrP,
pubmed-author:JonasMarkM,
pubmed-author:LevineRobertR,
pubmed-author:MakhloufHalaH,
pubmed-author:McHutchisonJohnJ,
pubmed-author:PatelKeyurK,
pubmed-author:RockeyDonD,
pubmed-author:Rodriguez-TorresMaribelM,
pubmed-author:SchultzMargaretM,
pubmed-author:ShiffmanMitchellM,
pubmed-author:StancilBrittB,
pubmed-author:TheodoreDickensD,
pubmed-author:WatsonHelenH,
pubmed-author:WebsterAlisonA
|
|
pubmed:copyrightInfo |
2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
138
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1365-73, 1373.e1-2
|
|
pubmed:dateRevised |
2010-7-21
|
|
pubmed:meshHeading |
pubmed-meshheading:20004661-Adult,
pubmed-meshheading:20004661-Aged,
pubmed-meshheading:20004661-Biopsy,
pubmed-meshheading:20004661-Double-Blind Method,
pubmed-meshheading:20004661-Female,
pubmed-meshheading:20004661-Hepatitis C, Chronic,
pubmed-meshheading:20004661-Humans,
pubmed-meshheading:20004661-Liver,
pubmed-meshheading:20004661-Liver Cirrhosis,
pubmed-meshheading:20004661-Male,
pubmed-meshheading:20004661-Middle Aged,
pubmed-meshheading:20004661-Oxazoles,
pubmed-meshheading:20004661-PPAR gamma,
pubmed-meshheading:20004661-Tyrosine
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection.
|
|
pubmed:affiliation |
Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina 27715, USA. mchut001@mc.duke.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
